{"transactions":[{"id":4630951,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":233040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630950,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":25.32,"value":15192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630949,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":26400,"price":24.4547,"value":645604.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":116343,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630948,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":1821,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":260040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":1820,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":27000,"price":22.367,"value":603909.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":1819,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":695828,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":287040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695827,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":21733,"price":27.3509,"value":594417.1097,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $27.17 to $27.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695826,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5267,"price":26.7895,"value":141100.2965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $26.17 to $27.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":137476,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695825,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":718213,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":314040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718212,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":7371,"price":30.2464,"value":222946.2144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718211,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":19629,"price":29.3424,"value":575961.9696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":123114,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718210,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":751938,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":341040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751937,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":20860,"price":23.0558,"value":480943.988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $22.60 to $23.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751936,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":6140,"price":22.252,"value":136627.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":136603,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751935,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":791841,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":368040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791840,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":21.9964,"value":24196.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $21.80 to $22.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791839,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":25900,"price":21.1931,"value":548901.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $20.79 to $21.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":116843,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791838,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,121 shares that were acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":807169,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"exercise","planned":true,"acquired":false,"shares":38460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":395040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":38460},"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":807168,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":38460,"price":25,"value":961500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":807167,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"exercise","planned":true,"acquired":true,"shares":38460,"price":5.2,"value":199992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":151082,"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":819783,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":433500,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":819782,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":27000,"price":21.2029,"value":572478.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":819781,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":139622,"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":826434,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":460500,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":826433,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":20.11,"value":241320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":826432,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":5.2,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":124622,"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":853660,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-09T20:01:04.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":20251,"price":15,"value":303765.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-098443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526098443/ownership.xml","form_type":"4"}},{"id":877410,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-27T23:54:34.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":54345,"price":12.7741,"value":694208.4645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.61 to $13.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":132873,"source":{"system":"sec-edgar","filing":"0001193125-26-083579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526083579/ownership.xml","form_type":"4"}},{"id":919540,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":284760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":284760,"derivative":{"exercise_price":11.94,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":284760},"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919539,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":201,"price":12.8971,"value":2592.3171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":187218,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919538,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":18251,"price":12.2573,"value":223707.9823,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":187419,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919537,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":47460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":205670,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":1280373,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-07T01:08:43.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":6851,"price":3.1614,"value":21658.7514,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from  $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":158210,"source":{"system":"sec-edgar","filing":"0000950170-25-015693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015693/ownership.xml","form_type":"4"}},{"id":1280372,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-07T01:08:43.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":7432,"price":2.988,"value":22206.816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":165061,"source":{"system":"sec-edgar","filing":"0000950170-25-015693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015693/ownership.xml","form_type":"4"}},{"id":1282075,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T00:34:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":318090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":318090,"derivative":{"exercise_price":2.91,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":318090},"source":{"system":"sec-edgar","filing":"0000950170-25-014813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014813/ownership.xml","form_type":"4"}},{"id":1282074,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-06T00:34:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":53015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":172493,"source":{"system":"sec-edgar","filing":"0000950170-25-014813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014813/ownership.xml","form_type":"4"}},{"id":1653653,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-09T02:04:52.000Z","date":"2024-02-07","kind":"sale","planned":false,"acquired":false,"shares":4083,"price":12.6198,"value":51526.6434,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.43 to $12.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":119478,"source":{"system":"sec-edgar","filing":"0000950170-24-012991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024012991/ownership.xml","form_type":"4"}},{"id":1653652,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-09T02:04:52.000Z","date":"2024-02-06","kind":"sale","planned":false,"acquired":false,"shares":4288,"price":12.5626,"value":53868.4288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.22 to $12.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":123561,"source":{"system":"sec-edgar","filing":"0000950170-24-012991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024012991/ownership.xml","form_type":"4"}},{"id":1659139,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T21:22:21.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":279593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":279593,"derivative":{"exercise_price":12.28,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":279593},"source":{"system":"sec-edgar","filing":"0000950170-24-011257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024011257/ownership.xml","form_type":"4"}},{"id":1659138,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-05T21:22:21.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":46599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 3, 2025, 1/3 on February 2, 2026 and 1/3 on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":46599,"source":{"system":"sec-edgar","filing":"0000950170-24-011257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024011257/ownership.xml","form_type":"4"}},{"id":1751455,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-02T20:49:54.000Z","date":"2023-11-01","kind":"sale","planned":false,"acquired":false,"shares":7507,"price":8.3914,"value":62994.2398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 7,507 shares that were acquired on October 31, 2023 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":81250,"source":{"system":"sec-edgar","filing":"0000950170-23-058314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017023058314/ownership.xml","form_type":"4"}},{"id":1979903,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T21:10:29.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":487500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":487500,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":487500},"source":{"system":"sec-edgar","filing":"0000899243-23-006736","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000089924323006736/doc4.xml","form_type":"4"}},{"id":1979902,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-02T21:10:29.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 1/3 on February 5, 2024, 1/3 on February 3, 2025 and 1/3 on February 2, 2026 subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":81250,"source":{"system":"sec-edgar","filing":"0000899243-23-006736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000089924323006736/doc4.xml","form_type":"4"}},{"id":2038217,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-02-01T21:11:13.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":18750,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-23-000024","document":"wf-form4_167528585798757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000024/wf-form4_167528585798757.xml","form_type":"4"}},{"id":2038216,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:11:13.000Z","date":"2023-01-30","kind":"tax_withholding","acquired":false,"shares":1301,"price":7.78,"value":10121.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":20097,"source":{"system":"sec-edgar","filing":"0001662579-23-000024","document":"wf-form4_167528585798757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000024/wf-form4_167528585798757.xml","form_type":"4"}},{"id":2038215,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:11:13.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":21398,"source":{"system":"sec-edgar","filing":"0001662579-23-000024","document":"wf-form4_167528585798757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000024/wf-form4_167528585798757.xml","form_type":"4"}},{"id":2232206,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-06-14T20:45:25.000Z","date":"2022-05-26","kind":"tax_withholding","acquired":false,"shares":1102,"price":7.01,"value":7725.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":17648,"source":{"system":"sec-edgar","filing":"0001209191-22-036712","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122036712/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-27"}},{"id":2252695,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-05-27T20:16:05.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":22500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-22-032514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032514/doc4.xml","form_type":"4"}},{"id":2252694,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-05-27T20:16:05.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":18750,"source":{"system":"sec-edgar","filing":"0001209191-22-032514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032514/doc4.xml","form_type":"4"}},{"id":2391237,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-02-16T21:30:19.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":26250,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001209191-22-010204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122010204/doc4.xml","form_type":"4"}},{"id":2391236,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-16T21:30:19.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":118000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":118000,"derivative":{"exercise_price":22.71,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":118000},"source":{"system":"sec-edgar","filing":"0001209191-22-010204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122010204/doc4.xml","form_type":"4"}},{"id":2442683,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T21:30:21.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":112292,"derivative":{"exercise_price":6.49,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-001700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122001700/doc4.xml","form_type":"4"}},{"id":2442682,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:30:21.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":1054,"price":32.657,"value":34420.478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-22-001700","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122001700/doc4.xml","form_type":"4"}},{"id":2442681,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:30:21.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":13946,"price":31.5895,"value":440547.167,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":16054,"source":{"system":"sec-edgar","filing":"0001209191-22-001700","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122001700/doc4.xml","form_type":"4"}},{"id":2442680,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:30:21.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":15000,"price":6.49,"value":97350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-22-001700","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122001700/doc4.xml","form_type":"4"}},{"id":2459263,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-23T21:10:12.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":127292,"derivative":{"exercise_price":6.49,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-071069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121071069/doc4.xml","form_type":"4"}},{"id":2459262,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-23T21:10:12.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":5000,"price":6.49,"value":32450.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-071069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121071069/doc4.xml","form_type":"4"}},{"id":2544133,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-12T20:30:24.000Z","date":"2021-10-08","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":132292,"derivative":{"exercise_price":6.49,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-060230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121060230/doc4.xml","form_type":"4"}},{"id":2544132,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-12T20:30:24.000Z","date":"2021-10-08","kind":"exercise","acquired":true,"shares":10000,"price":6.49,"value":64900.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-21-060230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121060230/doc4.xml","form_type":"4"}},{"id":2547861,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T20:53:11.000Z","date":"2021-10-01","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020."}],"balance_after":168108,"derivative":{"exercise_price":4.98,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-059512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121059512/doc4.xml","form_type":"4"}},{"id":2547860,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:53:11.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":5112,"price":45.9935,"value":235118.772,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.89 to $46.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-059512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121059512/doc4.xml","form_type":"4"}},{"id":2547859,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:53:11.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":8176,"price":45.3233,"value":370563.3008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.845. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":5112,"source":{"system":"sec-edgar","filing":"0001209191-21-059512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121059512/doc4.xml","form_type":"4"}},{"id":2547858,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:53:11.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":1712,"price":44.2502,"value":75756.3424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.57 to $44.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":13288,"source":{"system":"sec-edgar","filing":"0001209191-21-059512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121059512/doc4.xml","form_type":"4"}},{"id":2547857,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:53:11.000Z","date":"2021-10-01","kind":"exercise","acquired":true,"shares":15000,"price":4.98,"value":74700.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-059512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121059512/doc4.xml","form_type":"4"}},{"id":2619654,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-02T22:44:54.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020."}],"balance_after":183108,"derivative":{"exercise_price":4.98,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-049114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049114/doc4.xml","form_type":"4"}},{"id":2619653,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-02T22:44:54.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":15000,"price":45,"value":675000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-049114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049114/doc4.xml","form_type":"4"}},{"id":2619652,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-02T22:44:54.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":15000,"price":4.98,"value":74700.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-049114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049114/doc4.xml","form_type":"4"}},{"id":2640419,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-07T00:00:26.000Z","date":"2021-07-01","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":142292,"derivative":{"exercise_price":6.5,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-045691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121045691/doc4.xml","form_type":"4"}},{"id":2640418,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:00:26.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":1700,"price":38.38,"value":65246.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-045691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121045691/doc4.xml","form_type":"4"}},{"id":2640417,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:00:26.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":13300,"price":37.9263,"value":504419.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1700,"source":{"system":"sec-edgar","filing":"0001209191-21-045691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121045691/doc4.xml","form_type":"4"}},{"id":2640416,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-07T00:00:26.000Z","date":"2021-07-01","kind":"exercise","acquired":true,"shares":15000,"price":6.5,"value":97500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-045691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121045691/doc4.xml","form_type":"4"}},{"id":2755333,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-06T20:30:57.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":157292,"derivative":{"exercise_price":6.5,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-025664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121025664/doc4.xml","form_type":"4"}},{"id":2755332,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-06T20:30:57.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":10879,"price":38.0005,"value":413407.4395,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.59 to $38.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-025664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121025664/doc4.xml","form_type":"4"}},{"id":2755331,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-06T20:30:57.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":4121,"price":37.1581,"value":153128.5301,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.545 to $37.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":10879,"source":{"system":"sec-edgar","filing":"0001209191-21-025664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121025664/doc4.xml","form_type":"4"}},{"id":2755330,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-06T20:30:57.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":15000,"price":6.5,"value":97500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-025664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121025664/doc4.xml","form_type":"4"}},{"id":2858234,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-16T21:15:39.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":87850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021."}],"balance_after":87850,"derivative":{"exercise_price":45.54,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":87850},"source":{"system":"sec-edgar","filing":"0001209191-21-010707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121010707/doc4.xml","form_type":"4"}}]}